Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

Non-small cell lung cancer (NSCLC) is a type of cancer that begins in the tissues of the lungs, the two spongy organs in your chest that help your body absorb oxygen. Lung cancer is the third most ...

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated ...

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

AbbVie ABBV announced that it has submitted a biologics license application (BLA) to the FDA seeking accelerated approval for ...

Survival in NSCLC improved with guideline-concordant care in lung cancer, and several factors can be addressed to reach more ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Incurable lung cancer could soon become treatable, according to experts conducting a world-first trial on the NHS.